http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-20001662-A3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5a9f51ef690ed8682c3cf2c41ec50c5 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 |
filingDate | 1998-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a16ab3803831fbafd4a3187589c39488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85651dca1d11f58e3a75d453258c637d |
publicationDate | 2000-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CZ-20001662-A3 |
titleOfInvention | Topical Formulation |
abstract | In the present invention, there is disclosed a topical formulation for the treatment of a dermatological condition, which comprises an immunosuppressive macrolide being selected from the group consisting of sirolimus, FK506, SDZ ASM 981 and pharmacologically active analogues, derivatives or pro-drugs thereof and a skin permeation modulator being selected from the group consisting of alkanoic acids and alkenic acids with the proviso that in case the immunosuppressive macrolide is FK506 then the permeation modulator differs from oleic acid wherein the skin permeation modulator and macrolide or the pharmacologically active analogue, derivative or pro-drug thereof are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced. |
priorityDate | 1998-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.